Gemphire Therapeutics Falls 20% After Oral Cholesterol Drug Trial Results

This post was originally published on this site

Gemphire Therapeutics (NASDAQ: GEMP) shares are trading lower after the company announced trial results for evaluating the safety, and tolerability of oral gemcabene.

The oral formulation of gemcabene is being developed for the treatment of hypercholesterolaemia which is an excess of cholesterol in the bloodstream. Three of the five patients tested showed decreases in TG levels while one patient discontinued treatment.

Gemphire shares were trading down 22.5% at 92 cents at time of publication.

Related Links:

Gemphire Therapeutics’ Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

© 2019 Benzinga does not provide investment advice. All rights reserved.